Form 4: Metagenomi's Chief Medical Officer, Sarah Noonberg, Reports Stock and Option Awards

Sarah Noonberg, Chief Medical Officer of Metagenomi, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On April 1, 2025, Sarah Noonberg, the Chief Medical Officer of Metagenomi, Inc., reported transactions involving the company's securities.
• Noonberg acquired 14,000 restricted stock units (RSUs) at a price of $0.
• These RSUs vest with 25% vesting on June 5, 2026, and the remainder vesting in 12 equal quarterly installments thereafter, contingent upon continued service.
• Noonberg also acquired options to purchase 84,000 shares of common stock at an exercise price of $1.32.
• These options vest with 25% vesting on April 1, 2026, and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• Following these transactions, Noonberg directly owns 114,374 shares of common stock and options to purchase 84,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices, indicating confidence in the company's future.

Positives

• The grant of RSUs and stock options to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company's success.

Industry Context

Stock options and RSU grants are common compensation practices in the biotechnology industry to attract and retain key personnel.

Comparison to Industry Standards

• Equity compensation packages for Chief Medical Officers in biotech companies typically include a mix of stock options and restricted stock units.
• The vesting schedules are fairly standard, designed to incentivize long-term commitment.
• Comparable companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize similar equity compensation strategies.

Stakeholder Impact

• The equity grants align management's interests with those of shareholders, potentially driving long-term value creation.

Key Dates

Keywords

Metagenomi, Sarah Noonberg, Chief Medical Officer, Form 4, RSUs, Stock Options, Beneficial Ownership, Vesting